NST-628

N/A

Report date: 2024/06/27 20:00:09
NMEFirst In Class

Base Information

Drug NameNST-628
Drug Alias NameNST-628NEST-1
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionRAF serine/threonine protein kinase modulatorsDual specificity mitogen-activated protein kinase kinase modulators
TargetsRAF serine/threonine protein kinaseDual specificity mitogen-activated protein kinase kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNested Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNested Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A